Keyphrases
Clinical Practice
100%
Chronic Lymphocytic Leukemia
100%
Ibrutinib
100%
Idelalisib
100%
Approved Drugs
100%
Obinutuzumab
100%
Rituximab
50%
Leukemia Cells
50%
Chemoimmunotherapy
50%
Frontline Therapy
50%
Chlorambucil
50%
Overall Survival
25%
Adverse Effects
25%
Progression-free Survival
25%
Response Rate
25%
Relapsed or Refractory Acute Myeloid Leukemia
25%
Cell Survival
25%
Minimal Residual Disease
25%
Tolerability
25%
Durable Remission
25%
Phosphoinositide 3-kinase (PI3K)
25%
Adverse Prognostic Factor
25%
Antibody-dependent Cellular Cytotoxicity
25%
Improved Outcomes
25%
Effective Treatment
25%
Retreatment
25%
Long Follow-up
25%
Deletion 17p
25%
B-cell Receptor Signaling
25%
Bruton's Tyrosine Kinase
25%
Anti-CD20 Antibody
25%
Side Effect Profile
25%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
100%
Idelalisib
100%
Ibrutinib
100%
Obinutuzumab
100%
Rituximab
60%
Leukemia
40%
Chlorambucil
40%
Side Effect
20%
Overall Survival
20%
Remission
20%
Progression Free Survival
20%
Tolerability
20%
Phosphatidylinositol 3 Kinase
20%
Minimal Residual Disease
20%
Bruton Tyrosine Kinase
20%
B Lymphocyte Receptor
20%
Antibody-Dependent Cell-Mediated Cytotoxicity
20%